On November 6, DexCom fell 5.01% in Regular Trading, trading at $84.04, with turnover of $147 million.
The most relevant recent catalyst in public information is a movement alert indicating that the stock is giving back part of its earlier post-earnings advance, even though the company had reported better-than-expected third-quarter results, raised full-year revenue guidance, and saw a higher price target from Barclays.
In the third quarter, adjusted EPS was $0.73 versus the $0.67 consensus, while revenue reached $1.344 billion versus the $1.327 billion expectation. DexCom also lifted its full-year revenue guidance to $5.20 billion-$5.25 billion. Additional analyst commentary highlighted U.S. share gains, near-record global new-patient additions, and progress converting nearly half of the U.S. installed base to the 15-day G7 sensor by year-end, while Barclays raised its price target to $120 from $115.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments